Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed August 19, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 72/100
What the filing says
On August 17–19, 2026, 3i, LP converted 3,116,164 shares of Series C Preferred Stock at $0.39/share and then sold 2,770,592 common shares at prices ranging from $0.1269 to $0.1798. The conversions and sales total approximately $497K in conversion value and ~$398K in sale proceeds, representing a sharp price decline post-conversion. No other material terms or counterparty details are disclosed.
Why this rating
3i's large conversion + immediate sell-off totals ~$900K transacted activity relative to $4M market cap (≈22% of company value). Sharp post-conversion price decline signals distress; conversion at $0.39 vs. sales at $0.13–$0.18 suggests forced liquidation or loss of confidence.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.